Sitka Biopharma

Sitka Biopharma is a biopharmaceutical startup founded in 2013 and based in Canada. The company has developed a novel polymer platform technology aimed at improving drug absorption for cancer treatments. Its lead candidate is a formulation designed to enhance the treatment benefit for bladder cancer by enabling taxane drugs to adhere to and penetrate the bladder wall, thus improving the efficacy and tolerability of the chemotherapies. Sitka Biopharma has received a $1.20M Venture Round investment on 11 February 2019 from the Centre for Drug Research and Development, which is a clear indication of investor confidence in the potential of the company's technology and product pipeline. With preclinical proof-of-concept in place, the company’s immediate objective is to secure regulatory approval to initiate clinical trials. The slogan "We're transforming chemotherapies to further benefit patients by enhancing efficacy & improving tolerability" encapsulates the company's vision and value proposition.